Importance to the field: Pulmonary arterial hypertension (PAH) is a morbid condition with
high mortality if left untreated. Bosentan is an effective treatment option for group 1 …

Pulmonary hypertension is a severe progressive disease with a marked morbidity and a
high mortality attributed to right heart failure. Bosentan, a dual endothelin receptor …

Endothelin receptor antagonism has emerged as an important therapeutic approach in
pulmonary arterial hypertension (PAH). Bench to bedside scientific research has clearly …

Pulmonary arterial hypertension (PAH) is a progressive disease that, without treatment,
ultimately results in right heart failure and death. For the majority of patients with advanced …

In addition to its potent vasoconstricting effect, endothelin (ET)-1 induces proliferation of
pulmonary vascular cells and appears to play a pathogenic role in the development of …

Pulmonary arterial hypertension (PAH) is a debilitating disease associated with significant
morbidity and a high mortality if left untreated. Over the past 5 years, there have been …

Study objectives We report on the long-term safety and efficacy of bosentan treatment in
patients with pulmonary arterial hypertension (PAH). Background In a preceding study …

Background: Pulmonary arterial hypertension (PAH) is a deadly disease with limited
treatment options. Objectives: The objectives of this study were to assess the effects of …

Bosentan (Tracleer®) is an orally administered dual endothelin-1 (ET-1) receptor antagonist
approved for use in patients with WHO class II (mildly symptomatic) pulmonary arterial …

The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which is
effective in the treatment of pulmonary arterial hypertension (PAH). This review critically …